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ABSTRACT
Introduction: New vaccines are being
developed to improve the efficacy of seasonal
influenza immunization in elderly persons aged
C65 years. These products require clinical and
economic evaluation to aid policy decisions.
Methods: To address this need, a two-part
model has been developed, which we have
applied to examine the potential clinical and
economic impact of vaccinating elderly persons
with adjuvanted trivalent inactivated influenza
vaccine (aTIV) relative to conventional trivalent
(TIV) and quadrivalent (QIV) vaccines. We
compared outcomes in the US population for
(1) aTIV in persons aged C65 years and QIV in
all other age cohorts; (2) QIV in all cohorts; (3)
TIV in all cohorts. Low, average, and high
intensity seasons with low, average, and high
vaccine match scenarios were compared.
Probabilistic sensitivity analysis was conducted
within each discrete scenario to explore the
impact of variation in model inputs on
potential outcomes.
Results: Assuming current vaccination
coverage rates in the US population with
(a) 25% better efficacy of adjuvanted versus
non-adjuvanted vaccine against any strain and
(b) 35% better efficacy of non-adjuvanted
vaccine against matched B versus mismatched
B strains, use of aTIV in persons aged C65 years
and QIV in persons \65 years could reduce
influenza cases by 11,166–1,329,200,
hospitalizations by 1365–43,674, and deaths
by 421–11,320 versus use of QIV in all cohorts.
These outcomes are reflected in a corresponding
increase in quality-adjusted life-years (QALYs)
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of 3003–94,084. If the prevalence of
mismatched influenza B was [54.5% of all
circulating strains, use of QIV in all cohorts
would offset the clinical benefits of aTIV.
Elderly aTIV or QIV vaccination was associated
with improved outcomes over non-adjuvanted
TIV in many of the scenarios, particularly in low
match seasons of any intensity. Total cost
savings (including direct and indirect
healthcare costs plus productivity impacts)
with aTIV in the elderly versus QIV in the
whole population ranged from $27 million (low
intensity, low match) to $934 million (high
intensity, high match). Univariate sensitivity
analysis of relative vaccine prices in the average
intensity, average match scenario indicated that
aTIV could be marginally cost saving relative to
QIV at the currently published Medicare price
for influenza vaccines offering enhanced
efficacy in the elderly. Elderly vaccination
with aTIV was associated with a higher overall
cost compared with TIV in only two scenarios
(low intensity with average or high match); the
incremental cost/QALY relative to TIV was
$9980 in the average match scenario and
$28,800 in the high match scenario.
Conclusions: Vaccination of persons aged
C65 years with aTIV has the potential to
provide clinical and economic benefit relative
to QIV and TIV. The new model allows the
assessment of various alternative strategies for
available influenza vaccines.
Funding: Novartis Vaccines.
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INTRODUCTION
The clinical and economic burden of influenza
is significant, particularly in vulnerable
populations, such as children, persons with
compromised immune function, and the
elderly. Notably, the risk of influenza-related
complications increases with age [1–3],
influenza-associated hospitalizations are most
common among elderly aged C65 years
(especially in those with underlying medical
conditions) [4–8], and up to 90% of
influenza-attributable mortality is seen in this
cohort [9–11].
Significant direct healthcare costs are linked
to influenza in persons aged C65 years [6].
These costs are driven by substantial numbers
of influenza-related hospitalizations, and are
increasing as the overall population ages [9].
Moreover, influenza-related hospitalizations in
the elderly are associated with significant
disability and impairments in activities of
daily living. These effects have societal
implications as they can be long lasting, and
catastrophic disability after influenza
hospitalization is a significant problem in this
age cohort [12, 13]. Influenza vaccination in the
elderly provides substantial benefits [14], and
past cost-benefit and cost-effectiveness studies
from a number of countries have indicated that
this intervention in this age cohort is always
cost-effective and is frequently cost saving [15].
Influenza vaccination policy in most developed
countries, therefore, targets people aged
C65 years as part of the effort to reduce the
mortality and disability burden in this
population [16].
The efficacy of conventional inactivated
influenza vaccine [trivalent (TIV) or
quadrivalent (QIV)] decreases with advancing
age because of reduced production of
vaccine-specific antibodies [17]. Attempts to
increase immunogenicity have been made
with alternatives such as high-dose TIV (60 lg
of hemagglutinin (HA)/strain) [18] and an
intradermal vaccine [19]. Constant evolution
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of the influenza strains in circulation further
challenges vaccine protection with
approximately 35% reduction in efficacy
against mismatched versus matched strains
[20, 21]. As a result, QIV may offer benefit in
seasons where the B lineage selected for TIVs
does not match the dominant circulating strain
[22]. Notably, however, TIV adjuvanted with
the squalene-containing oil-in-water emulsion
MF59 (aTIV) increases seroprotection [23, 24]
and has been associated with a 25% reduction
in risk of hospitalization for influenza or
pneumonia versus TIV in the elderly
population aged C65 years [25]. Moreover, in
the elderly, aTIV has been reported to provide
better cross-reactivity against mismatched
strains than conventional vaccine [26].
As the economic burden of influenza is
disproportionately concentrated in the elderly
[27], improvements in vaccine immunogenicity
and efficacy in this group have economic
implications that warrant investigation.
Economic modeling is an important and
generally accepted method for estimating the
economic effects of an intervention [28]. A
two-part epidemiologic and economic model
was, therefore, developed to assess the clinical
and economic impact of vaccination with aTIV
in persons aged C65 years and QIV in those aged
\65 years versus QIV or TIV in all age cohorts.
METHODS
Scenarios of Interest
This analysis compared clinical and economic
outcomes over a 1-year period in the United
States (US) population for three vaccination
strategies: (1) aTIV in those C65 years (elderly)
and QIV in all other age cohorts; (2) QIV in all
cohorts; (3) TIV in all cohorts. We compared
outcomes in nine discrete scenarios for low,
average, and high intensity (i.e.,
transmissibility) seasons, factoring in low,
average, and high vaccine match against
circulating seasonal strains, in a 3 9 3 matrix.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
The average match scenarios (based on the
arithmetic means of strain circulation in the US
from 1999–2000 through 2013–2014 [29–33])
were 48.3%, 30.4%, 11.0%, and 10.3% for
A/H3N2, A/H1N1, B/Victoria, and B/Yamagata,
respectively. The low and high match scenarios
were based on the 2000/2001 season, during
which there was a very high prevalence of
influenza B/Yamagata (1.7%, 51.9%, 0%, and
46.4% for A/H3N2, A/H1N1, B/Victoria, and
B/Yamagata, respectively).
The TIV and aTIV vaccines contain the
dominant circulating B strain (B/Yamagata) in
the high match scenarios, but not in the low
match scenarios. We also investigated a
breakeven scenario for vaccine match,
modeled for a low intensity season in which
the low attack rate minimizes the clinical
impact of vaccine efficacy. We assumed
(a) 25% better efficacy of adjuvanted versus
non-adjuvanted vaccine against any strain and
(b) 35% better efficacy of non-adjuvanted
vaccine against matched B versus mismatched
B strains.
The Two-Part Model
The model is programmed in Microsoft Excel,
and consists of a compartmental, dynamic
‘‘epidemiologic module’’ to estimate the
number of influenza cases and a
tree-structured ‘‘outcomes module’’ to estimate
complications, hospitalizations, deaths,
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life-years, quality-adjusted life-years (QALYs),
and costs associated with influenza cases over
a 1-year period (Fig. 1). The model assumes no
adverse events of influenza vaccination or
treatment, and mutual exclusivity of
complications. It also does not consider the
impact of strain mutation within a season, and
recovered/protected patients remain immune
for the duration of the simulation.
Epidemiologic Module
The ‘‘epidemiologic module’’ simulates the
transmission of seasonal influenza with
a susceptible-infectious-recovered/protected/
removed (SIR) model consisting of 6
compartments (Fig. 2). It estimates the
dynamic changes over one year with or
without vaccination (three unique
age-stratified strategies can be defined) in the
uninfected, infected with influenza, and the
recovered/protected/removed populations. The
population size is constant and proportions in
the different compartments (or health states)
can vary by age cohort i (0–3 years, 4–6, 7–9,
10–19, 21–34, 35–49, 50–64, 65–69, 70?). No
patients enter or leave the system over the
modeled year, and proportions in each
compartment sum to 1. Patients recovered/
protected/removed from infection (including
patients who die as a result of infection) are
fully immune and, therefore, cannot be
re-infected or infect others for the remainder
of the simulation (effectively removed from the
simulation).
As illustrated in Fig. 2, in the proportion of
the population that will be vaccinated (Cvi),
some people who receive vaccination are
susceptible (Si) and some are already protected
by previous vaccination or influenza exposure
(Ri). Among those not yet protected (Si),
vaccination can be successful (the individual
enters compartment VRi) or unsuccessful (enters
compartment VSi). Vaccine efficacy (1 - Pi)
determines distributions over the VSi and VRi
compartments. All persons already protected
before vaccination (Ri) will move to
compartment VRi.
The rate at which individuals in age cohort
i transition from susceptible Si to infected/
infectious Ii is the force of infection, ki.
Patients who are not fully protected after
Fig. 1 The two-part epidemiologic and economic model. QALY quality-adjusted life-year
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vaccination (VSi) can be infected, but at a rate
lower than or equal to unvaccinated
individuals, represented by bki, where
0\b B 1. Upon infection with influenza,
individuals recover according to rate a and
move to Ri (or VRi); they are immune to
further influenza infection for the remainder
of the year and, therefore, cannot infect others
(i.e., effectively removed from the simulation).
Changes in the proportion of patients over




¼ SiðtÞkiðtÞ  SiðtÞCviPi
 SiðtÞCvið1  PiÞ
dVSiðtÞ
dt
¼ VSiðtÞbkiðtÞ þ SiðtÞCviPi
dIiðtÞ
dt
¼ SiðtÞkiðtÞ  IiðtÞa
dVIiðtÞ
dt
¼ VSiðtÞbkiðtÞ  VIiðtÞa
dRiðtÞ
dt
¼ IiðtÞa  RiðtÞCvi
dVRiðtÞ
dt
¼ VIiðtÞa þ SiðtÞCvið1  PiÞ þ RiðtÞCvi
The force of infection ki(t) is the rate at
which susceptible individuals in age cohort i are
infected at time t. It is the summation of the
rates of infection at time t from all infected/






kijðtÞ ¼ r  cij  ui  nj  IjðtÞ ¼ bij  IjðtÞ
where:
r is the transmissibility parameter.
Fig. 2 The susceptible-infectious-recovered (SIR) com-
partment model for seasonal inﬂuenza. Si(t) = Fraction
of susceptible individuals to inﬂuenza in age cohort i at
time t. Ii(t) = Fraction of infectious individuals in age
cohort i at time t. Ri(t) = Fraction of recovered/protected/
removed from inﬂuenza in age cohort i at time
t. VSi(t) = Fraction of vaccinated but still susceptible for
inﬂuenza in age cohort i at time t. VIi(t) = Fraction of
inﬂuenza cases despite being vaccinated in age cohort i at
time t. VRi(t) = Fraction of vaccinated recovered/pro-
tected/removed in age cohort i at time t. Cvi = Vaccine
coverage in age cohort i. Pi = Probability of unsuccessful
vaccination in age cohort i. ki(t) = Force of infection in
age cohort i at time t. bki(t) = Force of infection in
vaccinated cohort in age cohort i at time t; a = Recovery
rate
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cij is the average number of contacts per day
between susceptible individuals in age cohort
i with infectious individuals in age cohort j.
ui is the susceptibility of a susceptible
individual in age cohort i.
fj is the infectivity of an infective individual
in age cohort j.
Ij(t) is the fraction of infectious individuals in
age cohort j at time t.
bij is the rate of infection of susceptible
individuals in age cohort i by infectious
individuals in cohort j (referred to as the
WAIFW or Who Acquired Infection from
Whom matrix; see Electronic Supplementary
Material (ESM) for further discussion of
derivation and implications for transmission
dynamics).
Inputs of the model include age-stratified
population [34], an age-stratified contact matrix
(c) representing interactions between
individuals in the population leading to spread
of the disease ([35], adapted to fit this model’s
age structure; Table S1), duration of infection
(1/t) (assumed gamma distribution with mean
of 4 days and standard deviation of 1 day
[36–38], strain circulation [29–33], vaccine
coverage by age [39], and vaccination efficacy
by strategy by level of vaccine match to
circulating strains by age [20, 21 25, 40]. The
susceptibility ui, infectivity fj, and transmission
r parameters are derived through a calibration
process described below and in the ESM. Full
details of these inputs are shown in
Tables S1–S8.
Outcomes Module
The ‘‘outcomes module’’ calculates the
outcomes associated with influenza according
to a tree structure (Fig. 3; Tables 1, 2, 3 [27, 39,
41–48]). Upon infection with influenza, a
person can experience symptoms (first chance
node and corresponding split path). If
symptoms are present, a patient might seek
medical consultation (second chance node).
Given medical consultation, antivirals and/or
other drugs might be prescribed (third and
fourth chance nodes). The conditional
probabilities of influenza-related complications
can be influenced by the prescription of
antivirals and other drugs. We assumed the
risk of complications to be the same with and
without vaccination (i.e., the risk of
complications is entirely dependent on
whether an individual is infected with
influenza). The probability of hospitalization
or death in the presence of a complication is the
result of the calibration process described
below. The conditional probabilities with their
sources are shown in Table S9.
Direct costs (US$) for medical care, including
medical consultation, prescriptions for
antivirals and other drugs [42], and costs of
complications with and without hospitalization
[42, 43, 49], were included (Table 1). Indirect
costs covered productivity losses based on the
severity of complications [27]. QALY reductions
for the duration of symptoms of influenza and
its complications (Table 2) and QALY losses due
to life-years lost due to fatal complications were
also included (Table 3). Life-years and QALYs
lost were discounted at 3% per annum.
Expected outcomes and costs for each new
influenza case were calculated by multiplying
the probability of each event as reflected in the
final branches of the tree with the
corresponding outcomes and costs. In
combination with the incidence of influenza
over the course of a 1-year period as estimated
with the ‘‘epidemiologic module’’, the expected
outcomes associated with influenza over this
period were obtained.
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Calibration of the Model
The model was calibrated to the age-stratified
number of cases based on age-stratified
estimated gross attack rates [27] and estimates
of influenza incidence [27, 29, 50] by adjusting
a factor for transmissibility (r) and age-specific
factors for susceptibility (ui). Conditional
probabilities for hospitalization and death by
complication according to age were then
calibrated to literature-based estimates [27]
(see the ESM for further detail).
Estimation of Model Outcomes
For each scenario and vaccination strategy of
interest, we conducted a probabilistic analysis
(second-order Monte Carlo simulation) by
Fig. 3 Outcomes associated with inﬂuenza. CVD cardiovascular disease
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Table 1 Input data: costs used in the model
Variable Estimate ($US) Source
Vaccine acquisition




All ages 21.00 Prosser [41]
Antiviral cost
All ages 92.35 Talbird et al. [42]
Medical consultation
All ages 98.79 Talbird et al. [42]
Complications
Pneumonia without hospitalization
All ages 206 Talbird et al. [42]
Pneumonia with hospitalization




All ages 221 Talbird et al. [42]
Bronchitis with hospitalization
0–19 3906 Talbird et al. [42]
20–64 7449
C65 8834
Other respiratory without hospitalization
All ages 221 Talbird et al. [42]
Other respiratory with hospitalization




All ages 2711 American Heart Association [43]
CVD with hospitalization
All ages 6017 American Heart Association [43]
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which variation in the model input parameters
(summarized with probability density
functions) was propagated through the model
to obtain distributions for the following
outcomes of interest: number of influenza
cases, complications, deaths, life-years lost,
Table 1 continued
Variable Estimate ($US) Source
Otitis media
All ages 224 Talbird et al. [42]
Lost productivity costs
Without complications





Extra loss due to minor complications
0–3 183 Molinari et al. [27]; weighted average of






Extra loss due to serious complications (pneumonia, bronchitis, CVD)
0–3 1333 Molinari et al. [27]; weighted average of







All ages 0 Assumed no additional days lost
aTIV adjuvanted trivalent inactivated inﬂuenza vaccine, CDC Centers For Disease Control And Prevention, CVD
cardiovascular disease, QIV Quadrivalent inactivated inﬂuenza vaccine, TIV trivalent inactivated inﬂuenza vaccine
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QALYs lost, and costs. The distributions for
these outcomes were summarized with the
mean (‘‘probabilistic mean’’), low (2.5th
percentile), and high (97.5th percentile)
estimates.
The model output was further used to
estimate budget impacts and cost-effectiveness
of the competing interventions.
RESULTS
The model outputs for the low, average, and
high intensity modeled seasons with low,
average, and high vaccine match are
summarized in Tables 4, 5, 6 and Figs. 4 and 5.
Assuming (a) 25% better efficacy of adjuvanted
versus non-adjuvanted vaccine against any
Table 2 Input data: QALY loss with inﬂuenza and impact of events
Variable Estimate Low High Distribution Source/comments
Minor complications 0.00000 0.00000 0.00000 Gamma Assumption
Pneumonia 0.01041 0.00674 0.01487 Gamma Lee et al. [44]
Bronchitis 0.00904 0.00585 0.01291 Gamma Lee et al. [44]
Other respiratory 0.00904 0.00585 0.01291 Gamma Lee et al. [44]
CVD 0.10000 0.06471 0.14284 Gamma Dyer et al. [45]
Otitis media 0.01382 0.00894 0.01974 Gamma Prosser et al. [46]
CVD cardiovascular disease, QALY quality-adjusted life-year
Table 3 Input data: life expectancy and QALY loss due to death
Age Discounted life-years lost
when dying
Discounted QALYs lost when dying Source/comments
Estimate Estimate Low High Distribution
0–3 30.8 27.7 25.0 30.5 Normal EQ-5D assumed 0.9 over rest of life
4–6 30.5 27.5 24.8 30.2 Normal EQ-5D assumed 0.9 over rest of life
7–9 30.2 27.2 24.5 29.8 Normal EQ-5D assumed 0.9 over rest of life
10–19 29.3 26.4 23.8 29.0 Normal EQ-5D assumed 0.9 over rest of life
20–34 27.2 24.5 22.1 26.9 Normal EQ-5D assumed 0.9 over rest of life
35–49 23.5 21.1 19.1 23.2 Normal EQ-5D assumed 0.9 over rest of life
50–64 18.3 15.8 14.2 17.3 Normal Fryback et al. [47] adjusted average for
remaining life-years
65–69 14.2 12.0 10.9 13.2 Normal Fryback et al. [47] adjusted average for
remaining life-years
70? 7.1 5.9 5.4 6.5 Normal Fryback et al. [47] adjusted average for
remaining life-years
Source: life expectancy: [48]
CDC Centers for Disease Control and Prevention, QALY Quality-adjusted life-year
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strain and (b) 35% better efficacy of
non-adjuvanted vaccine against matched B
versus mismatched B strains, clinical benefits
of aTIV vaccination in the population C65 years
and QIV in the population\65 years suggested
by the model (versus vaccination of the whole
population with QIV) included reductions in
influenza cases of 11,166–1,329,200 (low
estimate reflects probabilistic mean in low
intensity, low match scenario; high estimate
reflects probabilistic mean in high intensity,
high match scenario), 1365–43,674 fewer
hospitalizations, and 421–11,320 fewer deaths
(Table 4). These clinical outcomes were reflected
in gains of 3003–94,084 QALYs. As illustrated in
Fig. 4, elderly vaccination with aTIV or QIV was
associated with improved outcomes over
non-adjuvanted TIV in many of the scenarios,
particularly in low match seasons of any
intensity. Moreover, in all scenarios, elderly
vaccination with aTIV was shown by the model
to be at least as effective as QIV in reducing
cases and other clinical outcome rates (Fig. 4;
Tables 4, 5). The number of influenza cases
(95% Credible Interval [CrI]) when vaccinating
all age cohorts with TIV ranged from 5.6 million
(0.0–35.7) in the low intensity, high match
scenario to 45.9 million (1.4–71.4) in the high
intensity, low match scenario. Total costs (95%
CrI) when vaccinating all age cohorts with TIV
ranged from $6.2 billion (3.8–16.4) in the low
intensity, high match scenario to $19.8 billion
(4.9–29.4) in the high intensity, low match
scenario.
The breakeven analysis, which modeled a
low intensity season in which the difference
between elderly aTIV and QIV in number of
cases was as close to zero as possible, showed
that the prevalence of circulating mismatched
strains would have to exceed 54.5% for QIV to
offset the benefits of aTIV.
The potential impact of aTIV versus QIV
vaccination in the elderly on costs was split
evenly between direct savings ranging from $15
million (low intensity, low match) to
$475 million (high intensity, high match) and
indirect savings from $12 million to
$459 million (Fig. 5; Table 6). Elderly aTIV
vaccination was associated with increased
overall cost over TIV in only two scenarios
(low intensity with average or high match) but
still represented good value for money with an
incremental cost/QALY relative to TIV of $9980
in the average match scenario and $28,800 in
the high match scenario. In both these
scenarios, however, elderly aTIV dominated
QIV with lower cost (-$171,071; -$222,553)
and higher QALYs (14,676; 17,136). Univariate
sensitivity analysis of relative vaccine prices in
the average intensity, average match scenario
indicated that aTIV could be marginally cost
saving relative to QIV at current Medicare prices
for influenza vaccines (Fig. 6 [51–53]).
Inspection of variability of results across
scenarios showed that the outputs were most
sensitive to vaccine match, followed by season
intensity. The probabilistic nature of the model
was illustrated by the probabilistic mean, low,
and high estimates for each outcome within
each discrete scenario, reflecting variation of
inputs in observational studies and surveillance
data.
DISCUSSION
We demonstrate that vaccination of persons
aged C65 years with aTIV has the potential to
provide clinical and economic benefit relative
to QIV and TIV. The dynamic model described
herein can be used to inform policy decisions
regarding seasonal influenza vaccination.
Similar dynamic compartmental models have
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been described previously [54–57]. Importantly,
they enable herd immunity benefits of
vaccination, which are not adequately
addressed by static models, to be captured.
The use of dynamic models such as that
described here to inform policy making in
persons aged C65 years is particularly
pertinent because significant healthcare costs
are linked to influenza in this population [6].
Note that the present analysis was based on the
results of previous studies and other
information from the literature, and did not
involve the collection of any new data from
human or animal subjects.
In the US, a very broad routine annual
vaccination recommendation is in place (all
persons aged C6 months with no
contraindications) [58]. Moreover, the US
Centers for Disease Control and Prevention
(CDC) does not currently recommend any one
influenza vaccine product over another in the
elderly (i.e., no preference is expressed at
present for QIV, high-dose, or adjuvanted
vaccine over conventional TIV) [58]. As a
result of recent studies indicating increased
vaccine effectiveness of high-dose influenza
vaccine in the over-65 population [59, 60],
there is sentiment towards using the high-dose
vaccine in that population, despite the current
lack of a preferential recommendation for its
use. Additionally, as QIV supplies continue to
increase within the US, there appears to be
increasing support for its use in the general
population, again despite the lack of a
preferential recommendation for such use by
the CDC. Both the QIV and high-dose TIV
vaccines are covered by insurance in the US. Of
note, the high-dose TIV is covered by the
Medicare Part B program despite its higher
cost; this is significant, as the majority of the
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The effectiveness of current vaccination
recommendations in the elderly is under
debate, as conventional vaccines are reported
to provide suboptimal protection in this group
[7]. High-dose TIV uptake in the elderly is
expected to increase in the US and other
countries in the near future, but there remains
a need for additional vaccines offering
enhanced immunogenicity in this population
[62].
Adjuvantation of inactivated vaccines (e.g.,
with oil-in water adjuvants) has the potential to
address unmet influenza vaccination needs in
the elderly [16, 62], and has been reported to
provide better cross-reactivity against
mismatched strains than conventional
vaccines in the elderly in several studies [26,
63–65]. The potential for improved outcomes
with adjuvanted vaccine was apparent from the
model, which showed probabilistic mean
reductions in clinical outputs and overall costs
relative to QIV even in modeled low match
seasons. The breakeven analysis carried out after
the main simulations suggested that QIV would
only offer incremental benefit over aTIV in the
elderly if the proportion of mismatched strains
in circulation was as high as 54.5% or above, a
level which has not been observed in the US
over the last 15 years.
Of note, high-dose TIV has been associated
with a 24.2% increase in efficacy against
laboratory-confirmed influenza [59] and a 22%
increase in effectiveness for preventing probable
influenza infections and hospitalizations in
persons aged C65 years [60]. This suggests that
economic comparisons of high-dose TIV with
other inactivated influenza vaccine options
using the model would be of considerable
interest and could be the subject of a future
analysis. For now, and on the basis of the data
and assumptions built into the present model
and the above observations with high-dose
vaccine, we would expect such an analysis to
yield results comparable to those obtained here
with aTIV in subjects aged C65 years. Such a
hypothesis would require future confirmation,
however.
As reported above, the potential impact of
aTIV versus QIV on costs was split evenly
between direct and indirect savings. Direct
cost savings were derived from reduced
hospitalizations among the elderly, who
experience increased serious influenza
complication rates over younger populations
[27]. Indirect cost savings accrued mainly from
the impact on younger working relatives/
associates, who are likely to experience work
interruptions due to the need for visitation and
care giving, with accompanying losses of
productivity [27]. Sensitivity analysis of
vaccine prices in the average intensity, average
match scenario indicated that aTIV could be
marginally cost saving relative to QIV at current
Medicare prices.
The importance of indirect protection of
older persons through herd immunity effects
is illustrated by experience of influenza
outbreaks in residential institutions [5]. As
mentioned earlier, the structure of the SIR
model on which the analysis was based
accounts for herd immunity effects, through
which the elderly benefit from decreased
transmission of influenza among the broader
population as a result of vaccination [16].
The data used to populate the model were
subject to a number of limitations. Mannino
et al.’s study [25] demonstrating the 25%
cFig. 4 Graphic summary of the main clinical and life-year
outputs of the model. All values are probabilistic means
(see Tables 4 and 5 for 95% credible intervals for
probabilistically modeled values). aTIV adjuvanted TIV,
QALY quality-adjusted life-year, QIV quadrivalent inacti-
vated seasonal inﬂuenza vaccine, TIV trivalent inactivated
seasonal inﬂuenza vaccine
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reduction in risk of hospitalization for influenza
or pneumonia versus TIV in adults aged C65
years was observational only, did not assess
aTIV’s impact on the reduction of influenza
cases, and did not compare aTIV directly with
QIV [25]. There was no stratification other than
age in the model, with no account taken of
chronic disease status or residential/contact
status. The model does not account for adverse
effects of influenza vaccination. In addition,
costs were treated deterministically in the
model even though significant variation
occurs in clinical practice. Despite these
limitations, the findings are in line with what
would be expected for a vaccine offering
enhanced immunogenicity that has a
potentially positive effect on clinical outcomes
and costs relative to conventional vaccines,
given the known economic burden of
influenza [66] and the public health and
economic benefits of vaccination [66, 67].
CONCLUSION
We have developed a dynamic model to assist
vaccination policy decisions directing choices
between different formulations of seasonal
influenza vaccine. The US scenario modeled
suggests that vaccination of persons aged
C65 years with aTIV has the potential to
provide clinical and economic benefit relative
to QIV and TIV. We recommend further
investigation of the clinical and economic
impact of aTIV relative to other vaccine
formulations in the elderly.
Fig. 4 continued
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Fig. 5 Graphic summary of the main cost outputs of the
model. All values are probabilistic means (see Table 6 for
95% credible intervals for probabilistically modeled values).
aTIV adjuvanted TIV, QIV quadrivalent inactivated
seasonal inﬂuenza vaccine, TIV trivalent inactivated
seasonal inﬂuenza vaccine
482 Infect Dis Ther (2015) 4:459–487
ACKNOWLEDGMENTS
All named authors meet the International
Committee of Medical Journal Editors (ICMJE)
criteria for authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval to the
version to be published. Medical Writing
support for the development of this
manuscript was provided by Christopher Dunn
and Scott Malkin at Gardiner-Caldwell
Communications, Macclesfield, UK. Funding
for this support was provided by Novartis
Vaccines. Modeling support for the analyses
described in this manuscript was provided by
Fig. 5 continued
Fig. 6 Univariate sensitivity analysis of relative vaccine
prices in the average intensity, average match scenario.
aTIV adjuvanted trivalent inactivated inﬂuenza vaccine,
QALY quality-adjusted life-year, QIV quadrivalent inacti-
vated inﬂuenza vaccine
Infect Dis Ther (2015) 4:459–487 483
MAPI Values, Boston, MA, USA. Funding for this
support was provided by Novartis Vaccines.
Conflict of interest. Mark Mullikin, Norbert
Farkas, and Eckhardt Petri declare that they are
current or former employees of Novartis
Vaccines. Jeroen P. Jansen and Marc Van Ranst
have no conflict of interest. Litjen Tan has
served on scientific advisory boards for Pfizer,
Merck, Novartis, Temptime Corp., and
TruMedSystems within the past year. All
honoraria for these services were donated
directly to the Immunization Action Coalition.
Compliance with ethics guidelines. The
analysis in this article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Meier CR, Napalkov PN, Wegmu¨ller Y, Jefferson T,
Jick H. Population-based study on incidence, risk
factors, clinical complications and drug utilisation
associated with influenza in the United Kingdom.
Eur J Clin Microbiol Infect Dis. 2000;19:834–42.
2. Meyers DG. Myocardial infarction, stroke, and
sudden cardiac death may be prevented by
influenza vaccination. Curr Atheroscler Rep.
2003;2003(5):146–9.
3. Nicholson KG, Kent J, Hammersley V, Cancio E.
Acute viral infections of upper respiratory tract in
elderly people living in the community:
comparative, prospective, population based study
of disease burden. BMJ. 1997;315:1060–4.
4. Thompson WW, Shay DK, Weintraub E, et al.
Influenza-associated hospitalizations in the United
States. J Am Med Assoc. 2004;292:1333–40.
5. Menec VH, MacWilliam L, Aoki FY.
Hospitalizations and deaths due to respiratory
illnesses during influenza seasons: a comparison of
community residents, senior housing residents, and
nursing home residents. J Gerontol A Biol Sci Med
Sci. 2002;57:M629–35.
6. Menec VH, Black C, MacWilliam L, Aoki FY. The
impact of influenza-associated respiratory illnesses
on hospitalizations, physician visits, emergency
room visits, and mortality. Can J Public Health
Rev Can Sante´ Publique. 2003;94:59–63.
7. Simonsen L, Fukuda K, Schonberger LB, Cox NJ.
The impact of influenza epidemics on
hospitalizations. J Infect Dis. 2000;181:831–7.
8. Mullooly JP, Bridges CB, Thompson WW, on behalf
of the Vaccine Safety Datalink Adult Working
Group, et al. Influenza- and RSV-associated
hospitalizations among adults. Vaccine.
2007;25:846–55.
9. Thompson WW, Shay DK, Weintraub E, et al.
Mortality associated with influenza and respiratory
syncytial virus in the United States. J Am Med
Assoc. 2003;289:179–86.
10. Zamparo E, Little D. Immunogenicity and
effectiveness of virosomal adjuvanted vaccines
against influenza: a brief review of their utility in
the elderly population. J Prev Med Hyg.
2011;52:116–9.
11. Viboud C, Miller M. Health benefits of universal
influenza vaccination strategy. PLoS Med.
2008;5:e216.
12. McElhaney JE, Zhou X, Talbot HK, et al. The unmet
need in the elderly: how immunosenescence, CMV
infection, co-morbidities and frailty are a challenge
for the development of more effective influenza
vaccines. Vaccine. 2012;30:2060–7.
13. Monto AS, Ansaldi F, Aspinall R, et al. Influenza
control in the 21st century: optimizing protection
of older adults. Vaccine. 2009;27:5043–53.
14. Nichol KL. Efficacy and effectiveness of influenza
vaccination. Vaccine. 2008;26(Suppl. 4):D17–22.
484 Infect Dis Ther (2015) 4:459–487
15. Nichol KL. The efficacy, effectiveness and
cost-effectiveness of inactivated influenza virus
vaccines. Vaccine. 2003;21:1769–75.
16. Simonsen L, Taylor RJ, Viboud C, Miller MA,
Jackson LA. Mortality benefits of influenza
vaccination in elderly people: an ongoing
controversy. Lancet Infect Dis. 2007;7:658–66.
17. Sasaki S, Sullivan M, Narvaez CF, et al. Limited
efficacy of inactivated influenza vaccine in elderly
individuals is associated with decreased production
of vaccine-specific antibodies. J Clin Invest.
2011;121:3109–19.
18. Falsey AR, Treanor JJ, Tornieporth N, Capellan J,
Gorse GJ. Randomized, double-blind controlled
phase 3 trial comparing the immunogenicity of
high-dose and standard-dose influenza vaccine in
adults 65 years of age and older. J Infect Dis.
2009;200:172–80.
19. Coudeville L, Andre P, Bailleux F, Weber F, Plotkin
S. A new approach to estimate vaccine efficacy
based on immunogenicity data applied to influenza
vaccines administered by the intradermal or
intramuscular routes. Hum Vaccin. 2010;6:841–8.
20. Tricco AC, Chit A, Soobiah C, et al. Comparing
influenza vaccine efficacy against mismatched and
matched strains: a systematic review and
meta-analysis. BMC Med. 2013;11:153.
21. DiazGranados CA, Denis M, Plotkin S. Seasonal
influenza vaccine efficacy and its determinants in
children and non-elderly adults: a systematic
review with meta-analyses of controlled trials.
Vaccine. 2012;31:49–57.
22. McKeage K. Inactivated quadrivalent split-virus
seasonal influenza vaccine (Fluarix quadrivalent):
a review of its use in the prevention of disease
caused by influenza A and B. Drugs.
2013;73:1587–94.
23. De Donato S, Granoff D, Minutello M, et al. Safety
and immunogenicity of MF59-adjuvanted influenza
vaccine in the elderly. Vaccine. 1999;17:3094–101.
24. Squarcione S, Sgricia S, Biasio LR, Perinetti E.
Comparison of the reactogenicity and
immunogenicity of a split and a
subunit-adjuvanted influenza vaccine in elderly
subjects. Vaccine. 2003;21:1268–74.
25. Mannino S, Villa M, Apolone G, et al. Effectiveness
of adjuvanted influenza vaccination in elderly
subjects in northern Italy. Am J Epidemiol.
2012;176:527–33.
26. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted
vaccine: a safe and useful tool to enhance and
broaden protection against seasonal influenza
viruses in subjects at risk. Expert Opin Biol Ther.
2010;10:639–51.
27. Molinari N-AM, Ortega-Sanchez IR, Messonnier ML,
et al. The annual impact of seasonal influenza in
the US: measuring disease burden and costs.
Vaccine. 2007;25:5086–96.
28. Annemans L. Methods for economic evaluations.
In: Health economics for non-economists. Gent:
Academia Press; 2008. p. 29–79.
29. Reed C, Meltzer MI, Finelli L, Fiore A. Public health
impact of including two lineages of influenza B in a
quadrivalent seasonal influenza vaccine. Vaccine.
2012;30:1993–8.
30. Centers for Disease Control and Prevention (CDC).
Update: influenza activity—United States, 2010–11
season, and composition of the 2011–12 influenza
vaccine. MMWR Morb Mortal Wkly Rep.
2011;60:705–12.
31. Centers for Disease Control and Prevention (CDC).
Update: influenza activity—United States, 2011–12
season and composition of the 2012–13 influenza
vaccine. MMWR Morb Mortal Wkly Rep.
2012;61:414–20.
32. Centers for Disease Control and Prevention (CDC).
Influenza activity—United States, 2012–13 season
and composition of the 2013–14 influenza vaccine.
MMWR Morb Mortal Wkly Rep. 2013;62:473–9.
33. Epperson S, Blanton L, Kniss K, on behalf of the
Influenza Division NCfI, Respiratory Diseases CDC,
et al. Influenza activity—United States, 2013–14
season and composition of the 2014–15 influenza
vaccines. MMWR Morb Mortal Wkly Rep.
2014;63:483–90.
34. US Department of Commerce. Current Population
Survey (CPS)—a joint effort between the Bureau of
Labor Statistics and the Census Bureau—People and
Households—US Census Bureau [online
document]. US Census Bureau. 2012. http://www.
census.gov/cps/. Accessed 27 Oct 2014.
35. Del Valle SY, Hyman JM, Hethcote HW, Eubank SG.
Mixing patterns between age groups in social
networks. Soc Netw. 2007;29:539–54.
36. Biggerstaff M, Cauchemez S, Reed C, Gambhir M,
Finelli L. Estimates of the reproduction number for
seasonal, pandemic, and zoonotic influenza: a
systematic review of the literature. BMC Infect
Dis. 2014;14:480.
37. Cowling BJ, Fang VJ, Riley S, Peiris JSM, Leung GM.
Estimation of the serial interval of influenza.
Epidemiology. 2009;20:344–7.
Infect Dis Ther (2015) 4:459–487 485
38. Fraser C, Donnelly CA, Cauchemez S, on behalf of
the WHO Rapid Pandemic Assessment
Collaboration, et al. Pandemic potential of a
strain of influenza A (H1N1): early findings.
Science. 2009;324:1557–61.
39. Centers for Disease Control and Prevention (CDC).
Flu vaccination coverage, United States, 2013–14
Influenza Season/FluVaxView/Seasonal Influenza
(Flu)/CDC [online document]. 2014. http://www.
cdc.gov/flu/fluvaxview/coverage-1314estimates.
htm. Accessed 27 Oct 2014).
40. Blyth CC, Jacoby P, Effler PV, on behalf of the
WAIVE Study Team, et al. Effectiveness of trivalent
flu vaccine in healthy young children. Pediatrics.
2014;133:1218–25.
41. Prosser LA. Cost-effectiveness of Influenza Vaccine
[online document]. NIVS,May 16–17, 2012, Atlanta,
GA,USA. National Adult Influenza Immun. Summit.
http://www.izsummitpartners.org/summit/archive/
2012-nivs/. Accessed 28 Oct 2014.
42. Talbird SE, Brogan AJ, Winiarski AP, Sander B.
Cost-effectiveness of treating influenza-like illness
with oseltamivir in the United States. Am J Health
Syst Pharm. 2009;66:469–80.
43. Lloyd-Jones D, Adams RJ, Brown TM, on behalf of
the American Heart Association Statistics
Committee and Stroke Statistics Subcommittee,
et al. Heart disease and stroke statistics—2010
update: a report from the American Heart
Association. Circulation. 2010;121:e46–215.
44. Lee GM, Salomon JA, LeBaron CW, Lieu TA.
Health-state valuations for pertussis: methods for
valuing short-term health states. Health Qual Life
Outcomes. 2005;3:17.
45. Dyer MTD, Goldsmith KA, Sharples LS, Buxton MJ.
A review of health utilities using the EQ-5D in
studies of cardiovascular disease. Health Qual Life
Outcomes. 2010;8:13.
46. Prosser LA, Ray GT, O’Brien M, Kleinman K, Santoli
J, Lieu TA. Preferences and willingness to pay for
health states prevented by pneumococcal conjugate
vaccine. Pediatrics. 2004;113:283–90.
47. Fryback DG, Dunham NC, Palta M, et al. US norms
for six generic health-related quality-of-life indexes
from the National Health Measurement study. Med
Care. 2007;45:1162–70.
48. ftp.cdc.gov-/pub/health_Statistics/NCHS/




49. Fisman DN, Tuite AR. Estimation of the health
impact and cost-effectiveness of influenza
vaccination with enhanced effectiveness in
Canada. PLoS One. 2011;6:e27420.
50. Seasonal Flu [online document]. 2015. Flu.gov.
http://www.flu.gov/about_the_flu/seasonal/index.
html. Accessed 12 June 2015.
51. Centers for Medicare and Medicaid Services.
Physician fee schedule. 2014. https://www.cms.
gov/Medicare/Medicare-Fee-for-Service-Payment/
PhysicianFeeSched/index.html?redirect=/
PhysicianFeeSched/. Accessed 22 July 2015.
52. Centers for Medicare and Medicaid Services.
Clinical laboratory fee schedule. 2014. http://
www.cms.gov/Medicare/Medicare-Fee-for-Service-
Payment/ClinicalLabFeeSched/clinlab.html. Acces-
sed 22 July 2015.
53. Centers for Medicare and Medicaid Services.
Average sales price (ASP) drug pricing files. 2014.
http://www.cms.gov/Medicare/Medicare-Fee-for-
Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/
2014ASPFiles.html. Accessed 22 July 2015.
54. Nichol KL, Tummers K, Hoyer-Leitzel A, Marsh J,
Moynihan M, McKelvey S. Modeling seasonal
influenza outbreak in a closed college campus:
impact of pre-season vaccination, in-season
vaccination and holidays/breaks. PLoS One.
2010;5:e9548.
55. Coburn BJ, Wagner BG, Blower S. Modeling
influenza epidemics and pandemics: insights into
the future of swine flu (H1N1). BMC Med.
2009;7:30.
56. Knipl DH, Ro¨st G. Modelling the strategies for age
specific vaccination scheduling during influenza
pandemic outbreaks. Math Biosci Eng.
2011;8:123–39.
57. Damm O, Eichner M, Rose MA, et al. Public health
impact and cost-effectiveness of intranasal live
attenuated influenza vaccination of children in
Germany. Eur J Health Econ. 2015;16:471–88.
58. Centers for Disease Control and Prevention (CDC).
Prevention and Control of Seasonal Influenza with
Vaccines/Health Professionals/Seasonal Influenza
(Flu) [online document]. 2014. http://www.cdc.
gov/flu/professionals/acip/index.htm. Accessed 30
Oct 2014).
59. DiazGranados CA, Dunning AJ, Kimmel M, et al.
Efficacy of high-dose versus standard-dose influenza
vaccine in older adults. N Engl J Med.
2014;371:635–45.
486 Infect Dis Ther (2015) 4:459–487
60. Izurieta HS, Thadani N, Shay DK, et al. Comparative
effectiveness of high-dose versus standard-dose
influenza vaccines in US residents aged 65 years
and older from 2012 to 2013 using Medicare data: a
retrospective cohort analysis. Lancet Infect Dis.
2015;15:293–300.
61. Centers for Medicare and Medicaid Services.
Medicare Enrollment—National Trends
1966–2013. Medicare aged and disabled enrollees
by type of coverage. All areas, as of July 1,
1966–2013. Hospital and/or Supplementary
Medical Insurance, Medicare Enrollment Reports.
Baltimore: Centers for Medicare and Medicaid
Services; 2014.
62. Datamonitor Healthcare. Influenza vaccines
forecast (No. DMKC0107117). London: Informa
UK Ltd; 2014.
63. Baldo V, Baldovin T, Pellegrini M, et al.
Immunogenicity of three different influenza
vaccines against homologous and heterologous
strains in nursing home elderly residents. Clin
Dev Immunol. 2010;2010:517198.
64. Ansaldi F, Zancolli M, Durando P, et al. Antibody
response against heterogeneous circulating
influenza virus strains elicited by MF59- and
non-adjuvanted vaccines during seasons with
good or partial matching between vaccine strain
and clinical isolates. Vaccine. 2010;28:4123–9.
65. Orsi A, Ansaldi F, de Florentiis D, et al.
Cross-protection against drifted influenza viruses:
options offered by adjuvanted and intradermal
vaccines. Hum Vaccines Immunother.
2013;9:582–90.
66. Xue Y, Kristiansen IS, de Blasio BF. Modeling the
cost of influenza: the impact of missing costs of
unreported complications and sick leave. BMC
Public Health. 2010;10:724.
67. Preaud E, Durand L, Macabeo B, on behalf of the
Vaccines Europe Influenza Working Group, et al.
Annual public health and economic benefits of
seasonal influenza vaccination: a European
estimate. BMC Public Health. 2014;14:813.
Infect Dis Ther (2015) 4:459–487 487
